Integra LifeSciences (NASDAQ:IART) Reaches New 52-Week Low at $27.18

Integra LifeSciences Holdings Co. (NASDAQ:IART) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $27.18 and last traded at $27.27, with a volume of 657051 shares changing hands. The stock had previously closed at $29.38.

Analysts Set New Price Targets

A number of research firms have issued reports on IART. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Truist Financial cut their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a report on Wednesday, April 3rd. Finally, JMP Securities cut their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Stock Performance

The firm has a market cap of $2.23 billion, a P/E ratio of 34.23, a P/E/G ratio of 0.88 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The company’s 50 day moving average is $35.67 and its 200 day moving average is $38.83.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. During the same quarter last year, the company posted $0.94 earnings per share. The company’s revenue was down .3% compared to the same quarter last year. As a group, equities analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after buying an additional 72,294 shares during the period. Capital Research Global Investors increased its position in shares of Integra LifeSciences by 40.1% during the fourth quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock worth $187,149,000 after buying an additional 1,228,996 shares during the period. Cooke & Bieler LP increased its position in shares of Integra LifeSciences by 4.4% during the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after buying an additional 120,410 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Integra LifeSciences by 4.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock worth $70,340,000 after buying an additional 63,323 shares during the period. Finally, Victory Capital Management Inc. increased its position in shares of Integra LifeSciences by 19.5% during the third quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock worth $55,953,000 after buying an additional 238,816 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.